solomo.ai

Zota Health Care Ltd (ZOTA) — shareholding pattern, promoter holding, financials and share price

About Zota Health Care Ltd (ZOTA)

Zota Health Care Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ZOTA and on the BSE under scrip code 538426. Its ISIN is INE358U01012.

Zota Health Care Limited is a renowned pharmaceutical company that manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products across boundaries into the semi-regulated and regulated markets of Asian Countries markets of African Countries, Russian Countries & Latin America. [1]

Zota Health Care Limited is an Indian pharmaceutical and retail healthcare company operating a manufacturing/export arm and Davaindia, a rapidly scaled private-label generic pharmacy chain that markets medicinal, OTC and ayurvedic products with a strong focus on chronic therapies and affordability across its COCO and FOFO store formats.

Davaindia has become the principal growth engine, contributing roughly 76–80% of revenue in 9MFY26, with 2,331 active stores as of December 2025 and aggressive quarterly additions (276 stores in Q3FY26) that drove consolidated revenue of ₹14,295.14 lakhs in Q3FY26, reflecting ~98% year-on-year growth.

Listed peers in Pharmaceuticals: Innova Captab Ltd, Bliss GVS Pharma Ltd, Orchid Pharma Ltd, IOL Chemicals & Pharmaceuticals Ltd, RPG Life Sciences Ltd, Unichem Laboratories Ltd.

Valuation & Returns

10 Jul 2026

At ₹1,423 a share on 10 Jul 2026, Zota Health Care Ltd (ZOTA) was valued at a price-to-earnings ratio of -66.65x against an industry P/E of 36.41x and a price-to-book of 22.03x on a book value of ₹64.59 per share as of Mar 2025. Solomo computes return on equity of -33.11% and return on capital employed of -17.2% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.

P/E
-66.65x
Industry P/E
36.41x
P/B
22.03x
EPS (TTM)
₹-21.39
Book value / share
₹64.59
ROE
-33.11%
ROCE
-17.2%
ROA
-16.87%
Debt / equity
0.62x
Dividend yield
0.07%
EBITDA margin
3.71%
52-week range
₹1,026.2 – ₹1,740

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Zota Health Care Ltd (ZOTA) reported revenue of ₹539 crore, net profit of ₹-74 crore and earnings per share of ₹-21.35. That compares with revenue of ₹292 crore and net profit of ₹-57 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹163 crore and net profit ₹-14 crore (consolidated).

Consolidated annual results for Zota Health Care Ltd (ZOTA), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)131139180292539
Net profit (₹ cr)9-6-14-57-74
EPS (₹)3.54-2.29-5.55-19.7-21.35
Compound annual growth for Zota Health Care Ltd (ZOTA). Stock price CAGR is price return and excludes dividends.
Measure10Y5Y3Y1Y
Sales growth16.57%22.02%25.06%62.32%
Profit growth5.98%25.57%-6.61%-295.40%
Stock price CAGR-41%52%17%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 49.38% of Zota Health Care Ltd (ZOTA) (unchanged from the previous quarter). Market capitalisation was ₹4,928 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2017.

Largest disclosed public shareholders in Jun 2026: ASHA MUKUL AGRAWAL 5.14%, VALIANT MAURITIUS PARTNERS OFFSHORE LIMITED 3.38%, 3P INDIA EQUITY FUND 1 2.28%, MUKUL MAHAVIR AGRAWAL 2.13%, SINGULARITY EQUITY FUND I 2.02%, VALIANT MAURITIUS PARTNERS LIMITED 1.75%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202649.38%----
Mar 202649.38%----
Dec 202550.64%----
Sep 202555.81%----
Jun 202557.42%----
Mar 202559.72%----
Dec 202462.02%----
Sep 202462.4%----
Every quarter since Sep 2017 Filing data, not investment advice.